Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologistsMargaret Ottaviano, Vincenzo Montesarchio, Laura Attademo et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 19
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)Carmine De Angelis, Grazia Arpino, Dario Bruzzese et al.|ESMO Open|2021Cited by 12
Eribulin in combination with bevacizumab as second-line treatment for HER2–negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)Carmine De Angelis, Grazia Arpino, Dario Bruzzese et al.|Research Square|2020Cited by 1
Abstract P6-21-13: A phase II single arm trial evaluating the efficacy and safety of eribulin in combination with bevacizumab for second-line treatment of human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) progressing after first-line therapy with bevacizumab and paclitaxelSabino De Placido, Grazia Arpino, Michelino De Laurentiis et al.|Cancer Research|2019Cited by 0